SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-192874
Filing Date
2022-07-13
Accepted
2022-07-13 16:10:34
Documents
12
Period of Report
2022-07-13
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d267419d8k.htm   iXBRL 8-K 28125
  Complete submission text file 0001193125-22-192874.txt   150545

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20220713.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20220713_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20220713_pre.xml EX-101.PRE 11253
6 EXTRACTED XBRL INSTANCE DOCUMENT d267419d8k_htm.xml XML 3370
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 221081173
SIC: 2834 Pharmaceutical Preparations